Feed PRAX
PR

Praxis Precision Medicines, Inc. PRAX NASDAQ · Healthcare · United States

$328.13 +1.04% +$3.37

Summary

43 / 100 · Bulios Score

What speaks for it

  • It holds more cash than debt: $361.9M against $732.0K.

What to watch

  • It passes only 2 of the 9 points of the Piotroski financial health test.
  • The price moves much more than the market (beta 2.84).

Bulios Scoring describes a company's quality and track record, not its future return. A high score is not a buy signal. Learn more

Score in detail

Price

Is it expensive?

Looks expensive
Valuation in detail

Is it growing?

Yes, fast

Revenue (USD)

Diluted EPS (USD)

  • Analyst estimate

There is not enough revenue history yet to say how fast it grows.

Growth in detail

Does it make money?

Over the last 12 months it made a loss of $359.4M.

Profitability in detail

Is it financially healthy?

Yes

Over the last 12 months it spent more cash than it brought in. It holds more cash than debt.

Financial health in detail

Does it pay a dividend?

No

It pays no dividend.

Dividends in detail

What do analysts expect?

Mildly positive

Today's price within the analysts' price targets

The average target of $618 is 88% above today's price. 78% of the analysts recommend buying.

Analysts in detail

What does it earn on?

Fiscal year 2024

By product

By region

The company reports no revenue by region.

License brings in 77% of revenue.

Segments in detail

We use essential cookies to run the website and optional analytics cookies to measure usage.

Privacy policy